表紙
市場調查報告書
商品編碼
948123

遺傳性血管性水腫:市場分析,流行病學,市場預測(至2030年)

Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 200 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2017年,七個主要市場的遺傳性血管性水腫(HAE)市場規模為174.175億美元。

該報告分析了世界上七個主要國家(美國,英國,德國,法國,意大利,西班牙和日本)的遺傳性血管性水腫(HAE)的流行病學趨勢和前景。市場的基本結構,當前的治療和未滿足的需求,患者人數趨勢的展望,按年齡,性別和國家劃分的詳細趨勢,已在市場/正在臨床試驗中的藥物概況,全球/國家市場我們將提供信息,例如規模和推動/抑制市場的主要因素。

內容

第1章主要注意事項

第2章遺傳性血管性水腫(HAE):市場概述

  • 2017年HAE總市場份額(%)
  • 2030年HAE總市場份額(%)

第3章執行摘要

第4章組織

第5章流行病學和市場研究方法

第6章遺傳性血管性水腫(HAE):疾病概述

  • 簡介
  • 遺傳性血管性水腫的類型
  • 症狀
  • 臨床發現
  • 風險因素
  • HAE的病理生理和免疫學特徵
    • 水腫形成的機制
    • HAE遺傳學
  • 遺傳性血管性水腫的診斷
    • 檢查結果
    • 產前和產後診斷
    • HAE延遲診斷:嚴重後果的持續性問題

第7章流行病學和患者人數

  • 主要發現
  • 在七個主要國家/地區已診斷出的遺傳性血管性水腫的總患病率
  • 美國
    • 假設和依據
    • 美國確診的遺傳性血管性水腫患病率 在美國,
    • 特定類型的遺傳性血管性水腫病例 在美國,特定性別的遺傳性血管性水腫病例
    • 美國特定年齡段的遺傳性血管性水腫病例
    • 在美國特定地點的遺傳性血管性水腫病例
  • 歐洲
  • 德國
    • 德國在德國診斷出的遺傳性血管性水腫患病率
    • 德國特定類型的遺傳性血管性水腫病例
    • 德國特定性別的遺傳性血管性水腫病例
    • 德國特定年齡段的遺傳性血管性水腫病例
    • 德國特定地點的遺傳性血管性水腫病例
  • 法國
  • 意大利
  • 西班牙
  • 英國
    • 英國確診的遺傳性血管性水腫的總患病率
    • 英國特定類型的遺傳性血管性水腫病例
    • 英國特定性別的遺傳性血管性水腫病例
    • 英國特定年齡段的遺傳性血管性水腫病例
    • 英國特定地點的遺傳性血管性水腫病例
  • 日本
    • 日本特定性別的遺傳性血管性水腫病例
    • 日本特定年齡的遺傳性血管性水腫病例

第8章遺傳性血管性水腫的治療

  • 按需治療
  • 預防性治療
  • 家庭療法和自我管理
  • WAO遺傳性血管性水腫管理指南
  • 日本補充研究小組發佈的《 2010年遺傳性血管性水腫(HAE)指南》
  • AAAAI過敏和哮喘治療指南
  • 國際遺傳性血管性水腫指南

第9章未滿足的需求

第10章非處方藥

  • 拓四郎:武田製藥
    • 藥物說明
    • 監管里程碑
    • 其他發展活動
    • 臨床發展
    • 安全性和有效性
    • 產品簡介
  • Firazil:夏爾/武田製藥
  • Cinryze:夏爾/武田製藥
  • 卡比托爾:夏爾/武田製藥有限公司
  • Hegarda:CSL Behring
    • 其他發展活動
  • 貝裡酸鹽:CSL Behring
  • Luconest:製藥集團

第11章新療法

  • 主要交叉比賽
  • BCX7353:BioCryst製藥
    • 藥物說明
    • 其他發展活動
    • 臨床發展
    • 安全性和有效性
    • 產品簡介
  • IONIS-PKK-LRx:Ionis Pharmaceuticals
  • KVD900:KalVista Pharmaceuticals
  • CSL312:CSL白令

第12章遺傳性血管性水腫:七個主要市場分析

  • 主要發現
  • 七個主要國家的遺傳性血管性水腫的市場規模

第13章七種主要市場前景

  • 美國市場規模
    • 遺傳性血管性水腫市場的美國總市場
    • 按需治療的美國遺傳性血管性水腫市場
    • 長期預防性治療在美國遺傳性血管性水腫的市場規模
  • 德國
    • 德國遺傳性血管性水腫的總市場規模
    • 按需治療的德國遺傳性血管性水腫市場
    • 通過長期預防性療法治療遺傳性血管性水腫的德國市場
  • 法國
  • 意大利
  • 西班牙
    • 西班牙遺傳性血管性水腫的總體市場規模
  • 英國
    • 英國遺傳性血管性水腫市場總市場
    • 按需治療英國遺傳性血管性水腫市場
    • 長期預防療法在英國遺傳性血管性水腫市場
  • 日本

第14章市場增長因素

第15章市場壁壘

第16章SWOT分析

第17章市場准入和贖回

第18章案例研究

  • 遺傳性血管性水腫(HAE):復發性腹痛的原因
  • 遺傳性II型血管性水腫:成年後反覆出現嚴重腹痛的最初症狀
  • 一名女性患者的遺傳性I型血管性水腫:病例報告

第19章行業專家意見(hol)

第20章參考文獻

第21章附錄

  • 調查方法

第22章:DelveInsight服務內容

第23章免責聲明

第24章:關於Delve Insight

目錄
Product Code: DIMI0066

DelveInsight's 'Hereditary Angioedema (HAE) - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Hereditary Angioedema (HAE), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hereditary Angioedema (HAE) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted HAE symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hereditary Angioedema (HAE) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Hereditary Angioedema (HAE) Disease Understanding and Treatment Algorithm

Hereditary Angioedema (HAE) Overview

Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx. It is classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE). Identification of the novel polymorphisms in several genes leading to modification in the clinical phenotype of HAE is a relatively recent phenomenon.

The clinical features of HAE are recurrent and unpredictable spontaneous edema attacks. Traumas, infections, stress, or medical procedures are potential triggers for HAE attacks, and occasionally, angioedema could be associated with prodromal signs, including erythema marginatum. The severity and timing of HAE attacks are unpredictable, mainly due to the lack of a complete understanding of the underlying mechanisms. Also, swelling without urticaria is the feature of most HAE attacks, regardless of the molecular basis

HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.

Despite advances in testing procedures and better disease recognition, the diagnosis of HAE still presents considerable challenges for physicians, particularly in the primary care setting. Diagnosis is made through a careful evaluation of clinical symptoms and family history and confirmed using laboratory testing.

Hereditary Angioedema (HAE) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Hereditary Angioedema (HAE) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Hereditary Angioedema (HAE) market report gives a thorough understanding of HAE symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides HAE symptoms of treatment algorithms and treatment guidelines for HAE symptoms in the US, Europe, and Japan.

Hereditary Angioedema (HAE) Epidemiology

The Hereditary Angioedema symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hereditary Angioedema (HAE) epidemiology segmented as the Total diagnosed Prevalent of Hereditary Angioedema, Gender-specific cases of Hereditary Angioedema, Age-specific cases of Hereditary Angioedema, Type-specific cases of Hereditary Angioedema, Site-specific cases of Hereditary Angioedema, the report includes the Prevalent scenario of HAE symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hereditary Angioedema (HAE) Epidemiology

The epidemiology segment also provides the Hereditary Angioedema (HAE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total Diagnosed Prevalent population of Hereditary Angioedema (HAE) in 7MM countries was estimated to be 14,435 cases in 2017.

Hereditary Angioedema (HAE) Drug Chapters

The drug chapter segment of the Hereditary Angioedema (HAE) report encloses the detailed analysis of HAE marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hereditary Angioedema (HAE) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

The market overall has been segmented into two treatment strategies that are commonly used for HAE are on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible. Long-term prophylaxis of attacks reduces disease burden, also Short-term (or periprocedural) prophylaxis treatment is taken before activities that are known to trigger attacks.

The goal of treatment for acute attacks is to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible. Treatments fall into three categories: C1-INH concentrates (plasma-derived [Berinert, CSL Behring] or Recombinant [Ruconest, Pharming Group]), kallikrein inhibitor (ecallantide [Kalbitor, Takeda]), and bradykinin receptor antagonist (icatibant [Firazyr, Takeda). Since treatment during an attack helps shorten attack duration, guidelines recommend the same. Medications for acute treatment are delivered either via intravenous infusion or subcutaneous injection, and home and/or self-administration are preferred due to the unpredictability of attacks.

Products detail in the report…

Hereditary Angioedema (HAE) Emerging Drugs

BCX7353 (BioCryst Pharmaceuticals)

BCX7353-also known as Berotralstat-is a novel, oral, once-daily, highly, selective inhibitor of plasma kallikrein currently in development for the prevention and treatment of angioedema attacks in patients diagnosed with HAE.

BioCryst Pharmaceuticals is actively preparing for commercial infrastructure for successful launches in the US & EU, and The FDA has accepted the NDA filing for BCX7353 and has also submitted a marketing authorization application (MAA) in Europe. For the Japan region, to ease the commercial activities company entered in agreement with Tori Pharmaceuticals. It has also been submitted JNDA of BCX7353as prophylactic treatment for HAE Type I and Type II. If approved, Berotralstat would be 1st approved prophylactic HAE therapy in Japan as well as in first targeted therapy in Europe. Besides, BioCryst Pharmaceuticals expects three regulatory approvals for Berotralstat in 2020 and early 2021 to prevent HAE attacks

Products detail in the report…

Hereditary Angioedema (HAE) Market Outlook

The Hereditary Angioedema (HAE) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Hereditary Angioedema (HAE) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Hereditary Angioedema (HAE) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Hereditary Angioedema (HAE) market in 7MM is expected to change in the study period 2017-2030.

At present, the therapeutic market size of HAE in the US is mainly accounted for by the management options consisting of various approved therapies.

Short-Term prophylaxis is aimed to prevent potentially fatal laryngeal edema. Medications for short-term prophylaxis are the same as those used for on-demand treatment. The goal of long-term prophylaxis for HAE patients is to prevent or reduce the frequency and severity of HAE attacks.

Key Findings

This section includes a glimpse of the Hereditary Angioedema (HAE) market in 7MM. The market size of HAE in the seven major markets was found to be USD 1,741.75 million in 2017.

The United States Market Outlook

This section provides the total Hereditary Angioedema (HAE) market size and market size by therapies in the United States.

The United States accounts for the highest market size of HAE in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Three classes of drugs - C1-INHs, 17 alpha-alkylated androgens, and antifibrinolytics - are currently being used for long-term prophylaxis of HAE type 1 and 2, and a monoclonal antibody, lanadelumab, was recently approved in the US and Europe for this indication.

The C1-INHs work by increasing the C1-INH levels in the body to prevent the accumulation of bradykinin and onset of angioedema. There are two C1-INH currently approved for long-term prophylaxis for HAE type 1 and 2 - Cinryze (Takeda) and Haegarda (CSL Behring).

EU-5 Countries: Market Outlook

The total Hereditary Angioedema (HAE) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Lanadelumab (Takhzyro, Takeda) is a newly-developed monoclonal antibody that was recently approved for long-term prophylaxis in HAE patients ages 12 and older. It inhibits plasma kallikrein, preventing the formation of bradykinin, and therefore, decreasing the risk of developing angioedema. It is administered subcutaneously every two or four weeks. The efficacy profile continues to position Takhzyro as a foundational HAE treatment in the US and good market opportunities in Germany, the UK, and other European regions.

"Both Haegarda and lanadelumab have the additional benefit of being subcutaneously administered, which may decrease the burden and complexity of administration and avoid complications due to repeated intravenous infusions"

Japan Market Outlook

The total Hereditary Angioedema (HAE) market size and market size by therapies in Japan are also mentioned.

Hereditary Angioedema (HAE) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Hereditary Angioedema (HAE) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Hereditary Angioedema (HAE) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hereditary Angioedema (HAE) key players involved in developing targeted therapeutics.

Major players include of KVD900 (KalVista Pharmaceuticals) for acute treatment, and BCX7353 (BioCrystc Pharmaceuticals), IONIS-PKK-LRx (Ionis Pharmaceuticals), CSL312 (CSL Behring) for prophylaxis during the forecast period [2020-2030]. These therapies are novel and their approval will have tremendous effects on the future.

IONIS-PKK-LRx (Ionis Pharmaceuticals), is expected to get launched in the US market by 2024.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Hereditary Angioedema (HAE) emerging therapies.

Reimbursement Scenario in Hereditary Angioedema (HAE)

Medications for HAE can be categorized into on-demand therapies, which are taken during an attack to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible. Short-term (or periprocedural) prophylaxis taken before activities is known to trigger attacks, whereas long-term prophylaxis reduces disease burden. Institute for Clinical and Economic Review (ICER) encouraged all stakeholders to suggest services (including treatments and mechanisms of care) that are currently used for people with HAE that could be reduced, eliminated, or made more efficient.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Hereditary Angioedema (HAE) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hereditary Angioedema (HAE) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Hereditary Angioedema (HAE) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Hereditary Angioedema (HAE), explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Hereditary Angioedema (HAE) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hereditary Angioedema (HAE) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hereditary Angioedema (HAE) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hereditary Angioedema (HAE) market

Report Highlights:

  • In the coming years, Hereditary Angioedema (HAE) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hereditary Angioedema (HAE) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for HAE. Launch of emerging therapies will significantly impact the Hereditary Angioedema (HAE) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HAE.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hereditary Angioedema (HAE) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Hereditary Angioedema (HAE) Pipeline Analysis
  • Hereditary Angioedema (HAE) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hereditary Angioedema (HAE) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Hereditary Angioedema (HAE) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Hereditary Angioedema (HAE) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What were the Hereditary Angioedema (HAE) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Hereditary Angioedema (HAE) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings of the market across 7MM and which country will have the largest Hereditary Angioedema (HAE) market Size during the forecast period (2017-2030)?
  • At what CAGR, the Hereditary Angioedema (HAE) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Hereditary Angioedema (HAE) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Hereditary Angioedema (HAE) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Hereditary Angioedema (HAE)?
  • What is the historical Hereditary Angioedema (HAE) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Hereditary Angioedema (HAE) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Hereditary Angioedema (HAE)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Hereditary Angioedema (HAE) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Hereditary Angioedema (HAE)?
  • What are the current treatment guidelines for the treatment of Hereditary Angioedema (HAE) in the USA, Europe, and Japan?
  • What are the Hereditary Angioedema (HAE) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hereditary Angioedema (HAE)?
  • How many therapies are developed by each company for the treatment of Hereditary Angioedema (HAE)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Hereditary Angioedema (HAE)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hereditary Angioedema (HAE) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hereditary Angioedema (HAE) and their status?
  • What are the key designations that have been granted for the emerging therapies for Hereditary Angioedema (HAE)?
  • What are the global historical and forecasted market of Hereditary Angioedema (HAE)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Hereditary Angioedema (HAE) market
  • To understand the future market competition in the Hereditary Angioedema (HAE) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hereditary Angioedema (HAE) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hereditary Angioedema (HAE) market
  • To understand the future market competition in the Hereditary Angioedema (HAE) market

Table of Contents

1. Key Insights

2. Hereditary Angioedema (HAE): Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of HAE in 2017
  • 2.2. Total Market Share (%) Distribution of HAE in 2030

3. Executive summary

4. Organizations

5. Epidemiology and Market Methodology

6. Hereditary Angioedema (HAE): Disease Overview

  • 6.1. Introduction
  • 6.2. Types of Hereditary Angioedema
  • 6.3. Symptoms
  • 6.4. Clinical Presentation
  • 6.5. Risk Factors
  • 6.6. Pathophysiologic and Immunologic Features of HAE
    • 6.6.1. Mechanisms of Edema Formation
    • 6.6.2. Genetics of HAE
  • 6.7. Diagnosis of Hereditary Angioedema
    • 6.7.1. Laboratory Findings
    • 6.7.2. Prenatal and Postnatal Diagnosis
    • 6.7.3. Delayed Diagnosis of HAE-A Persistent Problem with Serious Consequences

7. Epidemiology and Patient Population

  • 7.1. Key Findings
  • 7.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in 7MM
  • 7.3. United States
    • 7.3.1. Assumptions and Rationale
    • 7.3.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in the United States
    • 7.3.3. Type-Specific cases of Hereditary Angioedema in the US
    • 7.3.4. Gender-Specific cases of Hereditary Angioedema in the US
    • 7.3.5. Age-Specific cases of Hereditary Angioedema in the US
    • 7.3.6. Site-specific cases of Hereditary Angioedema in the US
  • 7.4. Europe
    • 7.4.1. Assumptions and Rationale
  • 7.5. Germany
    • 7.5.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in Germany
    • 7.5.2. Type-Specific cases of Hereditary Angioedema in Germany
    • 7.5.3. Gender-Specific cases of Hereditary Angioedema in Germany
    • 7.5.4. Age-Specific cases of Hereditary Angioedema in Germany
    • 7.5.5. Site-specific cases of Hereditary Angioedema in Germany
  • 7.6. France
    • 7.6.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in France
    • 7.6.2. Type-Specific cases of Hereditary Angioedema in France
    • 7.6.3. Gender-Specific cases of Hereditary Angioedema in France
    • 7.6.4. Age-Specific cases of Hereditary Angioedema in France
    • 7.6.5. Site-specific cases of Hereditary Angioedema in France
  • 7.7. Italy
    • 7.7.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in Italy
    • 7.7.2. Type-Specific cases of Hereditary Angioedema in Italy
    • 7.7.3. Gender-Specific cases of Hereditary Angioedema in Italy
    • 7.7.4. Age-Specific cases of Hereditary Angioedema in Italy
    • 7.7.5. Site-specific cases of Hereditary Angioedema in Italy
  • 7.8. Spain
    • 7.8.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in Spain
    • 7.8.2. Type-Specific cases of Hereditary Angioedema in Spain
    • 7.8.3. Gender-Specific cases of Hereditary Angioedema in Spain
    • 7.8.4. Age-Specific cases of Hereditary Angioedema in Spain
    • 7.8.5. Site-specific cases of Hereditary Angioedema in Spain
  • 7.9. UK
    • 7.9.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in the UK
    • 7.9.2. Type-Specific cases of Hereditary Angioedema in the UK
    • 7.9.3. Gender-Specific cases of Hereditary Angioedema in the UK
    • 7.9.4. Age-Specific cases of Hereditary Angioedema in the UK
    • 7.9.5. Site-specific cases of Hereditary Angioedema in the UK
  • 7.10. Japan
    • 7.10.1. Assumptions and Rationale
    • 7.10.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in Japan
    • 7.10.3. Type-Specific cases of Hereditary Angioedema in Japan
    • 7.10.4. Gender-specific cases of Hereditary Angioedema in Japan
    • 7.10.5. Age-specific cases of Hereditary Angioedema in Japan
    • 7.10.6. Site-specific cases of Hereditary Angioedema in Japan

8. Treatment of Hereditary Angioedema

  • 8.1. On-demand treatment
  • 8.2. Prophylactic treatment
  • 8.3. Home therapy and self-administration
  • 8.4. WAO Guideline for the Management of Hereditary Angioedema
  • 8.5. Guideline for Hereditary Angioedema (HAE) 2010 by the Japanese Association for Complement Research
  • 8.6. AAAAI Allergy and Asthma Medication Guide
  • 8.7. The International Hereditary Angioedema Guideline

9. Unmet Needs

10. Marketed drugs

  • 10.1. Takhzyro: Takeda
    • 10.1.1. Drug Description
    • 10.1.2. Regulatory Milestones
    • 10.1.3. Other Development Activities
    • 10.1.4. Clinical Development
    • 10.1.5. Safety and Efficacy
    • 10.1.6. Product Profile
  • 10.2. Firazyr: Shire/Takeda
    • 10.2.1. Drug Description
    • 10.2.2. Regulatory Milestones
    • 10.2.3. Other Development Activities
    • 10.2.4. Clinical Development
    • 10.2.5. Safety and Efficacy
    • 10.2.6. Product Profile
  • 10.3. Cinryze: Shire/Takeda
    • 10.3.1. Drug Description
    • 10.3.2. Regulatory Milestones
    • 10.3.3. Other Development Activities
    • 10.3.4. Clinical Development
    • 10.3.5. Safety and Efficacy
    • 10.3.6. Product Profile
  • 10.4. Kalbitor: Shire/Takeda
    • 10.4.1. Drug Description
    • 10.4.2. Regulatory Milestones
    • 10.4.3. Other Development Activities
    • 10.4.4. Clinical Development
    • 10.4.5. Safety and Efficacy
    • 10.4.6. Product Profile
  • 10.5. Haegarda: CSL Behring
    • 10.5.1. Drug Description
    • 10.5.2. Regulatory Milestones
    • 10.5.3. Other Developmental Activities
    • 10.5.4. Clinical Development
    • 10.5.5. Safety and Efficacy
    • 10.5.6. Product Profile
  • 10.6. Berinert: CSL Behring
    • 10.6.1. Drug Description
    • 10.6.2. Regulatory Milestones
    • 10.6.3. Safety and Efficacy
    • 10.6.4. Product Profile
  • 10.7. Ruconest: Pharming Group
    • 10.7.1. Drug Description
    • 10.7.2. Regulatory Milestones
    • 10.7.3. Other Developmental Activities
    • 10.7.4. Clinical Development
    • 10.7.5. Safety and Efficacy
    • 10.7.6. Product Profile

11. Emerging Therapies

  • 11.1. Key Cross Competition
  • 11.2. BCX7353: BioCryst Pharmaceuticals
    • 11.2.1. Drug Description
    • 11.2.2. Other Developmental Activities
    • 11.2.3. Clinical Development
    • 11.2.4. Safety and Efficacy
    • 11.2.5. Product Profile
  • 11.3. IONIS-PKK-LRx: Ionis Pharmaceuticals
    • 11.3.1. Drug Description
    • 11.3.2. Clinical Development
    • 11.3.3. Safety and Efficacy
    • 11.3.4. Product Profile
  • 11.4. KVD900: KalVista Pharmaceuticals
    • 11.4.1. Drug Description
    • 11.4.2. Other Developmental Activities
    • 11.4.3. Clinical Development
    • 11.4.4. Safety and Efficacy
    • 11.4.5. Product Profile
  • 11.5. CSL312: CSL Behring
    • 11.5.1. Drug Description
    • 11.5.2. Clinical Development
    • 11.5.3. Safety and Efficacy
    • 11.5.4. Product Profile

12. Hereditary Angioedema: 7 Major Market Analysis

  • 12.1. Key Findings
  • 12.2. Market Size of Hereditary Angioedema in 7MM

13. Seven Major Market Outlook

  • 13.1. United States Market Size
    • 13.1.1. The total market size of Hereditary Angioedema in the United States
    • 13.1.2. The market size of Hereditary Angioedema by On-Demand Therapies in the US
    • 13.1.3. The market size of Hereditary Angioedema by Long-Term Prophylactic Therapies in the US
  • 13.2. Germany
    • 13.2.1. The total market size of Hereditary Angioedema in Germany
    • 13.2.2. The market size of Hereditary Angioedema by On-Demand Therapies in Germany
    • 13.2.3. The market size of Hereditary Angioedema by Long-Term Prophylactic Therapies in Germany
  • 13.3. France
    • 13.3.1. The total market size of Hereditary Angioedema in France
    • 13.3.2. The market size of Hereditary Angioedema by On-Demand Therapies in France
    • 13.3.3. The market size of Hereditary Angioedema by Long-Term Prophylactic Therapies in France
  • 13.4. Italy
    • 13.4.1. The total market size of Hereditary Angioedema in Italy
    • 13.4.2. The market size of Hereditary Angioedema by On-Demand Therapies in Italy
    • 13.4.3. The market size of Hereditary Angioedema by Long-Term Prophylactic Therapies in Italy
  • 13.5. Spain
    • 13.5.1. Total Market Size of Hereditary Angioedema in Spain
    • 13.5.2. The market size of Hereditary Angioedema by On-Demand Therapies in Spain
    • 13.5.3. The market size of Hereditary Angioedema by Long-Term Prophylactic Therapies in Spain
  • 13.6. United Kingdom
    • 13.6.1. The total market size of Hereditary Angioedema in the United Kingdom
    • 13.6.2. The market size of Hereditary Angioedema by On-Demand Therapies in the UK
    • 13.6.3. The market size of Hereditary Angioedema by Long-Term Prophylactic Therapies in the UK
  • 13.7. Japan
    • 13.7.1. The total market size of Hereditary Angioedema in Japan
    • 13.7.2. The market size of Hereditary Angioedema by On-Demand Therapies in Japan
    • 13.7.3. The market size of Hereditary Angioedema by Long-Term Prophylactic Therapies in Japan

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Market Access and Reimbursement

18. Case studies

  • 18.1. Hereditary angioedema (HAE): a cause for recurrent abdominal pain
  • 18.2. Hereditary Angioedema Type II: First Presentation in Adulthood with Recurrent Severe Abdominal Pain
  • 18.3. Hereditary angioedema type I in a female patient: a case report

19. KOL Views

20. Bibliography

21. Appendix

  • 21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables

  • Table 1: A Comprehensive Table of Hereditary Angioedema Types
  • Table 2: A Comprehensive Table of Hereditary Angioedema Types
  • Table 3: Summary of the mutations described in F12, plasminogen (PLG), and angiopoietin (ANGPT1) genes resulting in HAE.
  • Table 4: Total diagnosed Prevalent Population of Hereditary Angioedema in 7MM (2017-2030)
  • Table 5: Total Diagnosed Prevalent Population of Hereditary angioedema in the US (2017-2030)
  • Table 6: Type-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Table 7: Gender-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Table 8: Age-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Table 9: Site-specific cases of Hereditary Angioedema in the US (2017-2030)
  • Table 10: Total Diagnosed Prevalent Population of Hereditary angioedema in Germany (2017-2030)
  • Table 11: Type-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Table 12: Gender-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Table 13: Age-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Table 14: Site-specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Table 15: Total Diagnosed Prevalent Population of Hereditary angioedema in France (2017-2030)
  • Table 16: Type-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Table 17: Gender-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Table 18: Age-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Table 19: Site-specific cases of Hereditary Angioedema in France (2017-2030)
  • Table 20: Total Diagnosed Prevalent Population of Hereditary angioedema in Italy (2017-2030)
  • Table 21: Type-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Table 22: Gender-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Table 23: Age-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Table 24: Site-specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Table 25: Total Diagnosed Prevalent Population of Hereditary angioedema in Spain (2017-2030)
  • Table 26: Type-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Table 27: Gender-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Table 28: Age-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Table 29: Site-specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Table 30: Total Diagnosed Prevalent Population of Hereditary angioedema in the UK (2017-2030)
  • Table 31: Type-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Table 32: Gender-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Table 33: Age-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Table 34: Site-specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Table 35: Total Diagnosed Prevalent Population of Hereditary angioedema in Japan (2017-2030)
  • Table 36: Type-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Table 37: Gender-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Table 38: Age-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Table 39: Site-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Table 40: Summary of treatments for hereditary angioedema
  • Table 41: Replacement therapy or immune-modulating medicines of hereditary angioedema
  • Table 42: Summary of recommendations
  • Table 43: Key cross competition
  • Table 44: Takhzyro, Clinical Trial Description, 2020
  • Table 45: Firazyr, Clinical Trial Description, 2020
  • Table 46: Cinryze, Clinical Trial Description, 2020
  • Table 47: Kalbitor, Clinical Trial Description, 2020
  • Table 48: Haegarda, Clinical Trial Description, 2020
  • Table 49: Ruconest, Clinical Trial Description, 2020
  • Table 50: Key cross competition - Phase III and II
  • Table 51: Key cross competition-Phase I
  • Table 52: BCX7353, Clinical Trial Description, 2020
  • Table 53: IONIS-PKK-LRx, Clinical Trial Description, 2020
  • Table 54: KVD900, Clinical Trial Description, 2020
  • Table 55: CSL312, Clinical Trial Description, 2020
  • Table 56: Market Size of Hereditary Angioedema in 7MM in USD Million (2017-2030)
  • Table 57: Total Market Size of Hereditary Angioedema in the US in USD Million (2017-2030)
  • Table 58: US Market Size of HAE by On-Demand Therapies, in USD Million (2017-2030)
  • Table 59: US Market Size of HAE by Long-Term Prophylaxis therapies, in USD Million (2017-2030)
  • Table 60: Total Market Size of Hereditary Angioedema in Germany, USD Millions (2017-2030)
  • Table 61: Germany Market Size of HAE by On-Demand Therapies, in USD Million (2017-2030)
  • Table 62: Germany Market Size of HAE by Long-Term Prophylaxis therapies, in USD Million (2017-2030)
  • Table 63: Total Market Size of Hereditary Angioedema in France, USD Millions (2017-2030)
  • Table 64: France Market Size of HAE by On-Demand Therapies, in USD Million (2017-2030)
  • Table 65: France Market Size of HAE by Long-Term Prophylaxis therapies, in USD Million (2017-2030)
  • Table 66: Total Market Size of Hereditary Angioedema in Italy, USD Millions (2017-2030)
  • Table 67: Italy Market Size of HAE by On-Demand Therapies, in USD Million (2017-2030)
  • Table 68: Italy Market Size of HAE by Long-Term Prophylaxis therapies, in USD Million (2017-2030)
  • Table 69: Total Market Size of Hereditary Angioedema in Spain, USD Millions (2017-2030)
  • Table 70: Spain Market Size of HAE by On-Demand Therapies, in USD Million (2017-2030)
  • Table 71: Spain Market Size of HAE by Long-Term Prophylaxis therapies, in USD Million (2017-2030)
  • Table 72: Total Market Size of Hereditary Angioedema in the UK, USD Millions (2017-2030)
  • Table 73: UK Market Size of HAE by On-Demand Therapies, in USD Million (2017-2030)
  • Table 74: UK Market Size of HAE by Long-Term Prophylaxis therapies, in USD Million (2017-2030)
  • Table 75: Total Market Size of Hereditary Angioedema in Japan, USD Millions (2017-2030)
  • Table 76: Japan Market Size of HAE by On-Demand Therapies, in USD Million (2017-2030)
  • Table 77:Japan Market Size of HAE by Long-Term Prophylaxis therapies, in USD Million (2017-2030)

List of Figures

  • Figure 1: Epidemiology and Market Methodology
  • Figure 2: Risk Factors of Hereditary Angioedema
  • Figure 3: C1 esterase inhibitor prevents the autoactivation of complement C1
  • Figure 4: C1 esterase inhibitor inactivates factors XIIa and XIIf, plasmin, and kallikrein
  • Figure 5: C1 esterase inhibitor modulates complement and contact system activation
  • Figure 6: Mechanism of activation of the contact system
  • Figure 7: Dysregulation of Coagulation, Complement, and Contact Cascades in Hereditary Angioedema
  • Figure 8: Kinin metabolism and the mutual interactions between the kinin, complement, hemostatic and fibrinolytic pathways
  • Figure 9: Summary of the genetic defects leading to the phenotype of hereditary angioedema
  • Figure 10: Various mutations reported in the SERPING1 gene
  • Figure 11: Counteracting influences of angiopoietin 1 and bradykinin on vascular endothelial cells
  • Figure 12: Diagnostic Algorithm for Hereditary Angioedema
  • Figure 13: A proposed diagnostic algorithm for evaluation of a suspected case of hereditary angioedema (HAE with normal C1 inhibitor function requires genetic analysis for diagnosis)
  • Figure 14: Total Diagnosed Prevalent Population of Hereditary Angioedema in 7MM (2017-2030)
  • Figure 15: Total Diagnosed Prevalence of Hereditary angioedema in the US (2017-2030)
  • Figure 16: Type-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Figure 17: Gender-Specific cases of Hereditary angioedema in the US (2017-2030)
  • Figure 18: Age-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Figure 19: Site-specific cases of Hereditary Angioedema in the US (2017-2030)
  • Figure 20: Total Diagnosed Prevalence of Hereditary angioedema in Germany (2017-2030)
  • Figure 21: Type-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Figure 22: Gender-Specific cases of Hereditary angioedema in Germany (2017-2030)
  • Figure 23: Age-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Figure 24: Site-specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Figure 25: Total Diagnosed Prevalence of Hereditary angioedema in France (2017-2030)
  • Figure 26: Type-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Figure 27: Gender-Specific cases of Hereditary angioedema in France (2017-2030)
  • Figure 28: Age-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Figure 29: Site-specific cases of Hereditary Angioedema in France (2017-2030)
  • Figure 30: Total Diagnosed Prevalence of Hereditary angioedema in Italy (2017-2030)
  • Figure 31: Type-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Figure 32: Gender-Specific cases of Hereditary angioedema in Italy (2017-2030)
  • Figure 33: Age-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Figure 34: Site-specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Figure 35: Total Diagnosed Prevalence of Hereditary angioedema in Spain (2017-2030)
  • Figure 36: Type-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Figure 37: Gender-Specific cases of Hereditary angioedema in Spain (2017-2030)
  • Figure 38: Age-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Figure 39: Site-specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Figure 40: Total Diagnosed Prevalence of Hereditary angioedema in the UK (2017-2030)
  • Figure 41: Type-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Figure 42: Gender-Specific cases of Hereditary angioedema in the UK (2017-2030)
  • Figure 43: Age-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Figure 44: Site-specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Figure 45: Total Diagnosed Prevalence of Hereditary angioedema in Japan (2017-2030)
  • Figure 46: Type-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Figure 47: Gender-specific cases of Hereditary angioedema in Japan (2017-2030)
  • Figure 48: Age-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Figure 49: Site-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Figure 50: Unmet Needs
  • Figure 51: Market Size of Hereditary Angioedema in USD Million (2017-2030)
  • Figure 52: Total Market Size of Hereditary Angioedema in the US, USD Millions (2017-2030)
  • Figure 53: US Market Size of HAE by On-Demand Therapies, USD Millions (2017-2030)
  • Figure 54: US Market Size of HAE by Long-Term Prophylaxis therapies, USD Millions (2017-2030)
  • Figure 55: Total Market Size of Hereditary Angioedema in Germany, USD Millions (2017-2030)
  • Figure 56: Germany Market Size of HAE by On-Demand Therapies, USD Millions (2017-2030)
  • Figure 57: Germany Market Size of HAE by Long-Term Prophylaxis therapies, USD Millions (2017-2030)
  • Figure 58: Total Market Size of Hereditary Angioedema in France, USD Millions (2017-2030)
  • Figure 59: France Market Size of HAE by On-Demand Therapies, USD Millions (2017-2030)
  • Figure 60: France Market Size of HAE by Long-Term Prophylaxis therapies, USD Millions (2017-2030)
  • Figure 61:Total Market Size of Hereditary Angioedema in Italy, USD Millions (2017-2030)
  • Figure 62: Italy Market Size of HAE by On-Demand Therapies, USD Millions (2017-2030)
  • Figure 63: Italy Market Size of HAE by Long-Term Prophylaxis therapies, USD Millions (2017-2030)
  • Figure 64: Total Market Size of Hereditary Angioedema in Spain, USD Millions (2017-2030)
  • Figure 65: Spain Market Size of HAE by On-Demand Therapies, USD Millions (2017-2030)
  • Figure 66: Spain Market Size of HAE by Long-Term Prophylaxis therapies, USD Millions (2017-2030)
  • Figure 67: Total Market Size of Hereditary Angioedema in the UK, USD Millions (2017-2030)
  • Figure 68: UK Market Size of HAE by On-Demand Therapies, USD Millions (2017-2030)
  • Figure 69: UK Market Size of HAE by Long-Term Prophylaxis therapies, USD Millions (2017-2030)
  • Figure 70: Total Market Size of Hereditary Angioedema in Japan, USD Millions (2017-2030)
  • Figure 71: Japan Market Size of HAE by On-Demand Therapies, USD Millions (2017-2030)
  • Figure 72: Japan Market Size of HAE by Long-Term Prophylaxis therapies, USD Millions (2017-2030)
  • Figure 73: Market Drivers
  • Figure 74:Market Barriers